Pneumonia Therapeutics Market 2020 growth factors, latest trend and regional analysis of leading players by 2026

Pneumonia Therapeutics Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

The global pneumonia therapeutics market is anticipated to observe a significant growth due to increasing incidences of pneumococcal disease and surging government initiatives towards pneumonia treatment. Pneumonia is a severe respiratory disease and it annually affects a significant number of the global population, calling for effective treatment options, which would fuel the industry outlook.

Pneumococcal disease, which is caused due to Streptococcus pneumonia, can severely infect the lungs and causes bacterial meningitis, middle ear infection, and blood infection among others. As per the CDC (Centers for Disease Control and Prevention), pneumococcal pneumonia is responsible for about 150,000 hospitalizations per year solely across the U.S., expediting business progression.

Request for a sample copy of this report @

In addition, the surging global population, with its increasing demographic of people aged 65 and above and children aged two and below, is likely to further boost the number of annual disease cases. This demographic is highly susceptible to this ailment as their immune systems are considerably weak and cannot effectively fight the infection. Pneumonia can thus prove to be fatal to this population group, creating a significant need for effective treatment.

According to a research report by GMI Inc., the global pneumonia therapeutics market is likely to surpass a valuation of $2.8 billion by 2026. 

With respect to drug class, the market is bifurcated into antibacterial drugs, antiviral drugs, and antifungal drugs. Of these, the antibacterial drugs segment dominated the industry with a revenue share of more than 60% in 2019. Antibacterial drugs are further classified into macrolides and quinolones. These drugs are commonly used for the treatment of pneumonia that is community-acquired. In addition, macrolides antibiotics like azithromycin, and clarithromycin among others are widely used to protect children from pneumonia, which should further augment the segment share.

In terms of the age group, the pneumonia therapeutics market is characterized by the geriatric, adult, and pediatric groups. Owing to children’s weak and underdeveloped immune systems, they are more vulnerable to pneumonia, which is expected to further push the pediatric age group segment growth.

In addition, children suffering from asthma problems or cystic fibrosis, or any other lung-related disorders makes them more susceptible to the illness, which would increase the demand for antibacterial and antiviral drugs. Based on the aforementioned factors, the pediatric segment is projected to grow at a CAGR of 7.5% throughout the study period.

Geographically, the North America pneumonia therapeutics market is estimated to observe significant growth opportunities led by the U.S. In fact, the U.S. pneumonia therapeutics market is slated to record a CAGR of more than 6.3% through the forecast timeframe.

This regional growth can be ascribed to the country’s growing geriatric population, which is creating the demand for pneumonia medications. In addition, the surging number of hospital admissions to treat pneumonia is also likely to enhance the regional market expansion.

The regional industry is also slated to foresee a significant rate of proliferation due to the strong presence of prominent market players like Allergan, and Abbott Laboratories. These industry players are increasingly focusing towards product innovations and several R&D initiatives, which is likely to push the regional industry outlook.

Request for customization @

Major pharmaceutical companies are increasingly making efforts to discover new treatment options that addresses the disease in a more effective and quick manner. Taking June 2020 for instance, the U.S. FDA approved Recarbrio for the treatment of ventilator-linked bacterial pneumonia and hospital-acquired bacterial pneumonia in patients aged 18 and older. Recarbrio was earlier approved by the FDA to treat patients suffering from complicated intra-abdominal infections and urinary tract infections that have very limited or no other treatment options.

The competitive landscape of the pneumonia therapeutics market is inclusive of players such as GlaxoSmithKline, AstraZeneca, Merck, Pfizer, Sanofi, Novartis, Mylan, Lupin Pharmaceuticals, Cipla, and Bayer among others.   

Partial Chapter of the Table of Content 

Chapter 2. Executive Summary

2.1. Pneumonia therapeutics industry 3600 synopsis, 2015 - 2026

2.1.1.  Business trends

2.1.2.  Drug class trends

2.1.3.  Age group trends

2.1.4.  Infection type trends

2.1.5.  Distribution channel trends

2.1.6.  Regional trends

Chapter 3. Pneumonia Therapeutics Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2015 - 2026

3.3. Industry impact forces

3.3.1.  Growth drivers Surging cases of pneumonia across the globe Rising number of ongoing clinical trials for vaccine development and drug molecules Increasing funding opportunities in R&D for new product development Presence of various manufacturers in developed economies

3.3.2.  Industry pitfalls and challenges Low treatment rates in developing economies

3.4. Growth potential analysis

3.4.1.  By drug class

3.4.2.  By age group

3.4.3.  By infection type

3.4.4.  By distribution channel

3.5. COVID-19 impact analysis

3.6. Product pipeline analysis

3.7. Porter’s analysis

3.8. PESTEL Analysis 

Browse full table of contents (TOC) of this report @